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Abstract
Introduction We performed gene expression analysis to identify
molecular predictors of resistance to preoperative concomitant
trastuzumab and paclitaxel followed by 5-fluorouracil, epirubicin,
and cyclophosphamide (T/FEC).
Methods Pretreatment fine-needle aspiration specimens from
45 patients with HER-2-overexpressing stage II to IIIA breast
cancer were subjected to transcriptional profiling and examined
for differential expression of various genes and gene sets. The
primary endpoint for tumor response was pathologic complete
response (pCR). Correlations between pCR and gene
expression were sought.
Results The overall pCR rate was 64%. Age, nuclear grade,
tumor size, nodal status, quantitative expression of estrogen and
HER-2 receptor mRNA, and HER-2 gene copy number showed
no correlation with pCR. Results of gene set enrichment
analysis suggested that the lower expression of genes involved
with CD40 signaling is associated with a greater risk of residual
cancer after the preoperative chemotherapy that includes
trastuzumab.
Conclusion CD40 signaling may play a role in determining
response to trastuzumab-plus-T/FEC therapy in patients with
HER-2-overexpressing breast cancer.
Introduction
The amplification of the HER-2 gene is associated with shorter
disease-free survival (DFS) and overall survival (OS) in
patients with early-stage and metastatic breast cancer [1-3].
The anti-HER-2 monoclonal antibody trastuzumab (Herceptin;
Genentech, Inc., South San Francisco, CA, USA) is an effec-
tive treatment for breast tumors with HER-2 gene amplifica-
tion, both alone and in combination with other therapies.
Randomized clinical trials have shown that the addition of tras-
tuzumab to cytotoxic chemotherapy improves DFS and OS in
patients with metastatic disease [4,5] and as adjuvant therapy
[6,7]. However, not all patients with HER-2-overexpressing
tumors benefit from trastuzumab therapy [8]. Approximately
30% of HER-2-overexpressing metastatic breast tumors show
an objective response to single-agent first-line trastuzumab
treatment, and most will eventually progress [9-11]. Similarly,
as many as 15% of early-stage HER-2-overexpressing breast
tumors will relapse despite adjuvant chemotherapy that
includes trastuzumab [6,7].
We recently reported results from a clinical trial in which 42
patients with operable HER-2-overexpressing breast cancer
were randomly assigned to receive either 6 months of preop-
erative T/FEC chemotherapy (four cycles of paclitaxel followed
CEP17 = centromeric sequence of chromosome 17; CI = confidence interval; DFS = disease-free survival; ER = estrogen receptor; FDR = false 
discovery rate; FISH = fluorescence in situ hybridization; FNA = fine-needle aspiration; GSEA = gene set enrichment analysis; IHC = immunohisto-
chemistry; NPV = negative predictive value; OS = overall survival; pCR = pathologic complete response; PR = progesterone receptor; RD = residual 
disease; T/FAC = paclitaxel followed by 5-fluorouracil, doxorubicin, and cyclophosphamide; T/FEC = paclitaxel followed by 5-fluorouracil, epirubicin, 
and cyclophosphamide.Breast Cancer Research    Vol 9 No 6    Esteva et al.
Page 2 of 8
(page number not for citation purposes)
by four cycles of 5-fluorouracil, epirubicin, and cyclophospha-
mide) alone or concomitant with weekly trastuzumab followed
by definitive surgery. An interim analysis showed that the
patients in the trastuzumab-plus-T/FEC group had a patho-
logic complete response (pCR) rate of 65% compared with
26% in the T/FEC-alone group (P <0.016) [12]. Because of
the large and significant difference in pCR rates, the rand-
omized study was closed after these results became available.
A single-arm extension study accrued 22 more patients to the
trastuzumab-plus-T/FEC arm to further characterize the effi-
cacy and toxicity of the regimen. In the second cohort, the pCR
rate was 55% (95% confidence interval [CI], 32% to 76%).
Because the achievement of pCR correlates closely with
improved DFS and OS [13,14], we were interested in examin-
ing the clinical and molecular tumor characteristics in the sub-
set of women with residual disease (RD) in our original and
extension trials. Our goal was to identify molecular predictors
of resistance to preoperative concomitant trastuzumab and T/
FEC by analyzing gene expression in specimens from pretreat-
ment fine-needle biopsies. The identification of markers of
resistance to trastuzumab-based chemotherapy could help in
the design of future clinical trials of novel agents with the
potential to overcome drug resistance.
Materials and methods
Patients
The therapeutic study and optional biopsy protocol were
approved by the institutional review board, and each patient
who participated gave written informed consent. Patient
accrual and inclusion and exclusion criteria have been
described previously [12,15]. Briefly, all patients in both the
original and extended trials were required to have histologi-
cally confirmed stage II to IIIA, HER-2-positive invasive breast
cancer. HER-2 positivity was defined as the overexpression of
HER-2 receptors (an immunohistochemistry [IHC] score of
greater than or equal to 3) or HER-2 gene amplification (a
HER-2  gene/centromeric sequence of chromosome 17
[CEP17] ratio of greater than 2, as measured by fluorescence
in situ hybridization [FISH]). Estrogen receptor (ER) and pro-
gesterone receptor (PR) expression levels were measured
using IHC.
The initial preoperative regimen consisted of four cycles of
paclitaxel at 225 mg/m2 given as a 24-hour infusion at 3-week
intervals followed by four cycles of FEC. Patients treated on
the open-label phase of the protocol received 80 mg/m2 pacl-
itaxel per week for a total of 12 weeks. The FEC regimen con-
sisted of 500 mg/m2 5-fluorouracil on days 1 and 4, 500 mg/
m2 cyclophosphamide on day 1, and 75 mg/m2 epirubicin on
day 1. Patients also received a loading dose of intravenous
trastuzumab (4 mg/kg over the course of 90 minutes) on day
1 of the first cycle of paclitaxel. Then, patients received 2 mg/
kg trastuzumab, administered intravenously over the course of
30 minutes weekly, during each week in which chemotherapy
agents were given. All patients underwent mammograms and
ultrasound imaging at baseline and during therapy. If, during
the course of treatment, imaging detected that a tumor had
shrunk to less than 2 cm, metallic markers were placed in the
tumor bed under ultrasonographic guidance.
At the completion of preoperative chemotherapy, all patients
had a modified radical mastectomy or lumpectomy and a sen-
tinel lymph node biopsy or axillary lymph node dissection,
depending on patient preference and the opinion of the sur-
geon. Grossly visible residual cancer was measured, and rep-
resentative cross-sections of the tumor were submitted for
histopathologic examination. When grossly visible residual
cancer was not found, the slices of the surgical specimen
were radiographed, and all areas of radiologically or architec-
turally abnormal tissue were submitted for histopathologic
study. A pCR was defined as no residual invasive cancer in the
breast and lymph nodes. Residual ductal carcinoma in situ
was allowed because it has no impact on long-term survival
[16].
Tissue processing and microarray analysis
Patients who participated in the original trial and its extension
were given the option of undergoing a one-time, pretreatment
fine-needle aspiration (FNA) of their primary tumor. Forty-five
patients consented to the procedure. Each FNA was per-
formed using a 23- or 25-gauge needle. Cells from two or
three passes were collected into vials containing 1 mL of RNA
later solution (Ambion, Inc., Austin, TX, USA) and stored at -
80°C. RNA was extracted from the FNA samples using the
RNAeasy kit (Qiagen Inc., Valencia, CA, USA). The amount
and quality of RNA were assessed with a DU-640 spectropho-
tometer (Beckman Coulter, Fullerton, CA, USA) and consid-
ered adequate for further analysis if the optical density 260/
280 ratio was greater than 1.8 and the total RNA yield was
greater than 1 μg. All FNA specimens met these quality control
criteria and were hybridized to Affymetrix U133A GeneChips
(Affymetrix, Santa Clara, CA, USA) as described previously
[17]. Expression data were quantified using dCHIP version 1.3
(available from [18]). All hybridization experiments met the
quality control standards of the study, with scaling factors
within threefold of one another, percentage present call rates
greater than or equal to 35%, percentage of probe set outliers
less than or equal to 15%, percentage of single-probe outliers
less than or equal to 5%, and 3':5' ratio less than 3. All gene
expression data were normalized to a standard reference chip
using the dCHIP software. The normalized gene expression
values were transformed to a log10 scale for further analysis.
Statistical analyses
Data analysis was performed using the statistical software
package S-PLUS (version 7; Insightful Corporation, Seattle,
WA, USA). We used univariate and multivariate logistic
regression analyses to examine associations between RD,
pCR, and clinical pathologic variables, including routine ERAvailable online http://breast-cancer-research.com/content/9/6/R87
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and PR status, Black's modified nuclear grade, tumor size, and
level of HER-2 gene amplification. To examine correlations
between the pathologic response to treatment and the mRNA
expression levels of single-gene molecular markers, including
ER, Ki67, and HER-2, we performed rank correlation tests as
well as unequal variance t tests. The probe sets that targeted
the most 3' end of each transcript were selected to represent
these genes of interest (ER: 205225_at, Ki67: 212021_s_at,
and HER-2: 216836_s_at). We have previously shown that
these probes correlate closely with clinical receptor status but
represent more quantitative measurements [19].
We used unequal variance t tests to identify genes that were
differentially expressed in specimens from patients with RD
and those with pCR. Beta uniform mixture analysis of the P val-
ues was used to estimate false discovery rates (FDRs) [20].
We also examined whether a 30-gene pharmacogenomic pre-
dictor of pCR previously developed by our group in patients
treated with T/FAC (in which doxorubicin [A] replaces the epi-
rubicin [E] in T/FEC) [17] would predict pCR in patients
treated with T/FEC plus trastuzumab. The code for this predic-
tor is available at [21].
We used gene set enrichment analysis (GSEA) to assess the
association between pCR, RD, and 1,275 distinct a priori-
defined gene sets. All of these gene sets are available to the
public and have been described in detail in a previous publica-
tion [22]. The goal of the GSEA was to determine whether
members of a particular gene set (that is, a list of 15 to 500
biologically interesting genes) tended to occur at the top or
bottom of the complete rank-ordered gene list. In this case, we
ranked the 22,283 probe sets measured by the U133A gene
chip based on the probe sets' correlation with pCR. We exam-
ined three groups of gene sets, including 319 gene sets cor-
responding to probes associated with 295 different
cryptogenic bands on 24 chromosomes, 522 gene sets corre-
sponding to genes involved in various metabolic and signaling
pathways, and 427 gene sets of expression neighborhoods
centered on cancer-related genes [22]. Complete linkage hier-
archical clustering was carried out using 1,792 probe sets
described as the 'revised intrinsic gene set' (supplementary
Table 1) and using a 1 – Pearson correlation coefficient [23].
Results
Forty-five women who received concomitant trastuzumab and
T/FEC volunteered for pretreatment FNA biopsies. Patient and
disease characteristics are presented in Table 1. Twenty-nine
patients (64%) achieved pCR after 24 weeks of preoperative
therapy. Age, nuclear grade, tumor size, nodal status, clinical
ER status, and HER-2 gene amplification level, as detected by
FISH, showed no significant association with pCR in either
univariate or multivariate logistic regression analyses. Quanti-
tative expression of the ER and HER-2  receptor and Ki67
mRNA levels also showed no significant association with pCR
in univariate analyses (Figure 1). Supervised cluster analysis
using the revised intrinsic probe sets showed two distinct
clusters, but these were not associated with known clinical
variables or with response to therapy (Figure 2). An unequal
variance t test identified 132 genes with P values of less than
0.01 which were seemingly differentially expressed between
cases of pCR and RD. However, the FDR associated with
these P values was near 100%. Therefore, we could not iden-
tify any genes that would discriminate between pCR and RD
with statistical confidence.
We also tested the accuracy of a 30-gene pharmacogenomic
predictor of pCR which had been previously developed from a
study of patients treated preoperatively with T/FAC. This pre-
dictor showed both high sensitivity (92%) and negative pre-
dictive value (NPV) (96%) in an independent validation
conducted in a cohort of T/FAC-treated patients [17]. The
Table 1
Patient and tumor characteristics
Characteristic Number of patients (percentage)
Age
<50 years 19 (42)
≥50 years 26 (58)
HER-2a
IHC (score 3+) 26 (58)
FISH-positive 42 (95)
Estrogen receptor-positive
Yes 17 (38)
No 28 (62)
Progesterone receptor-positive
Yes 10 (22)
No 35 (78)
Nuclear grade
Intermediate 14 (31)
High 31 (69)
Tumor size (baseline)
T1 5 (11)
T2 24 (53)
T3 8 (18)
T4 8 (18)
Nodal status (baseline)
N0 19 (42)
N1-N3 26 (58)
aAll tumors were HER-2-positive by either IHC (score, 3+) and/or 
FISH. Not every patient had both tests. Two tumors were 2+ by IHC 
and positive by FISH, and one tumor was 3+ by IHC and negative by 
FISH. FISH, fluorescence in situ hybridization; IHC, 
immunohistochemistry.Breast Cancer Research    Vol 9 No 6    Esteva et al.
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same 30-gene test showed a diminished sensitivity of 52%
(95% CI, 0.27 to 0.79) for predicting pCR in patients treated
with trastuzumab plus T/FEC. The NPVs and positive predic-
tive values were also low at 36% (95% CI, 0.17 to 0.59) and
65% (95% CI, 0.43 to 0.84), respectively. The overall accu-
racy was 51% (95% CI, 0.36 to 0.66) in the present cohort of
patients compared with 76% (95% CI, 0.62 to 0.87) in the val-
idation cohort, which did not receive trastuzumab.
However, because the original validation cohort included both
HER-2-positive and HER-2-negative tumors and the cohort of
the present study included only HER-2-positive tumors treated
with trastuzumab, it was unclear whether the diminished accu-
racy was due to the inclusion of trastuzumab or the application
of the predictor. We therefore calculated the performance
metrics for the subset of patients in the validation cohort who
had HER-2-positive tumors and compared them with the
results from the present study and found that overall accuracy,
sensitivity, and specificity remained high in this group of
patients (Table 2).
The evaluation of 1,275 distinct gene sets showed significant
enrichment for only one gene signature: the CD40 signaling
pathway, which involves 64 genes (supplementary Table 2).
Complete results from the GSEA are included in supplemen-
tary Table 3. Patients whose tumors expressed the CD40 sig-
nature were significantly more likely to achieve pCR. The FDR
associated with this observation was 0.0022 (Figure 3).
Discussion
This analysis of gene expression data, which included 22,277
probe sets corresponding to more than 14,000 genes,
Figure 1
Association between pathologic complete response (pCR) and HER-2, estrogen receptor (ER), and Ki-67 mRNA levels and HER-2 gene copy  number ratio shown by fluorescence in situ hybridization (FISH) Association between pathologic complete response (pCR) and HER-2, estrogen receptor (ER), and Ki-67 mRNA levels and HER-2 gene copy 
number ratio shown by fluorescence in situ hybridization (FISH). Association between pCR and (a) the mRNA expression levels of HER-2 (Spear-
man's rank correlation = 0.087; P = 0.69), (b) ER (Spearman's rank correlation = -0.052; P = 0.81), and (c) Ki-67 (Wilcoxon rank sum = 148; P = 
0.2) or (d) the level of HER-2 gene amplification shown by FISH (Wilcoxon rank sum = -0.45; P = 0.65). Each circle represents results from one 
case and has been grouped by response category (pCR or RD [residual disease]).Available online http://breast-cancer-research.com/content/9/6/R87
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revealed no robust gene expression differences between the
two subgroups of HER-2-positive patients (those with pCR
and those who had RD) treated with preoperative concomitant
trastuzumab and T/FEC. Relatively modest differences in gene
expression can have important biological implications if the
number of genes is large enough; however, the transcriptional
differences between the two response categories tested here
were subtle and thus not easily identified using t statistics.
Therefore, we subjected our data to GSEA, a more complex
analytical method than t statistics, which can detect subtle
gene expression differences for a priori-defined sets of genes
between two groups (for this study, patients with pCR and
those with RD). GSEA results indicated that patients whose
tumors showed decreased expression of the genes associ-
Figure 2
Hierarchical clustering with the revised intrinsic gene set Hierarchical clustering with the revised intrinsic gene set. Supervised cluster analysis using 1,792 intrinsic probe sets showed two distinct clusters 
among these HER-2-positive cases, but the clusters were not associated with known clinical variables or response to therapy. Cases with residual 
disease (RD) are marked with an asterisk. ER, estrogen receptor; pCR, pathologic complete response.
Table 2
Predictive performance (and 95% confidence interval) of the DLDA30 predictor in patients treated with preoperative chemotherapy
Breast tumors of any phenotype HER-2-positive breast tumors
Performance metrics Validation cohort
T/FACa
n = 51
Present study cohort
Trastuzumab + T/FEC
n = 45
Subset of validation cohort
T/FACa
n = 30
Area under the curve 0.877 (0.066) 0.565 (0.089) 0.81 (0.092)
Overall accuracy 0.76 (0.62–0.87) 0.51 (0.36–0.66) 0.67 (0.47–0.83)
Sensitivity 0.92 (0.64–1.00) 0.52 (0.33–0.71) 0.90 (0.56–1.00)
Specificity 0.71 (0.54–0.85) 0.50 (0.25–0.75) 0.55 (0.32–0.77)
Positive predictive value 0.52 (0.31–0.73) 0.65 (0.43–0.84) 0.50 (0.26–0.74)
Negative predictive value 0.96 (0.82–1.00) 0.36 (0.17–0.59) 0.92 (0.62–1.00)
aHess KR, Anderson K, Symmans WF, Valero V, Ibrahim N, Mejia JA, Booser D, Theriault RL, Buzdar AU, Dempsey PJ, et al. [17]. T/FAC, 
paclitaxel followed by 5-fluorouracil, doxorubicin, and cyclophosphamide; T/FEC, paclitaxel followed by 5-fluorouracil, epirubicin, and 
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ated with the CD40 signaling pathway were more likely to
have residual cancer after trastuzumab-plus-T/FEC chemo-
therapy. One of the reasons why we could not find more differ-
entially expressed gene sets may be the small sample size and
the low number of patients in the group who had RD after pre-
operative chemotherapy and trastuzumab treatment. It should
be noted that, in small pharmacogenomic studies, the associ-
ation between large-scale gene expression patterns and ER
status and grade represents substantial biological noise for
outcomes that are not associated with these clinical variables
[24].
HER-2  gene amplification (HER-2/CEP17 ratio of greater
than 2.0) and protein overexpression (IHC staining intensity of
greater than 3) remain the best predictors of response to tras-
tuzumab therapy [2,4]. According to these criteria, all patients
in the present study were HER-2-positive. We found no corre-
lation between the HER-2 gene copy number or semiquantita-
tive HER-2 mRNA levels and the amount of residual invasive
cancer after preoperative T/FEC-plus-trastuzumab therapy.
This suggests the existence of a threshold effect, in which a
HER-2/CEP17  ratio of greater than 2.0 would predict a
response to trastuzumab.
There are many research findings indicating the potential
oncogenic role of CD40. In particular, although CD40, a mem-
ber of the tumor necrosis factor receptor family, is expressed
in B lymphocytes, macrophages, fibroblasts, and endothelial
and epithelial cells, it is also expressed in a variety of hemato-
logic malignancies and solid tumors. For example, transfection
studies have shown that constitutive CD40 signaling plays an
important role in the transformation of murine fibroblasts, an
oncogenic effect that was inhibited by the suppression of the
nuclear factor-kappa B signaling pathway [25]. Similarly, the
treatment of human breast cancer cells with a recombinant
CD40 ligand (CD40L) inhibited cell growth in vitro and in vivo
[26,27]. Wingett and colleagues [28] observed that, in con-
trast to normal B cells, in which CD40 signaling provides a
potent survival signal, CD40 ligation in breast carcinoma cells
results in growth inhibition and enhanced susceptibility to Fas-
mediated apoptosis. Tong and colleagues [29], in their study
using CD40-positive (T47D and BT-20) and CD40-negative
(MCF-7 and ZR-75-1) cell lines, likewise examined the growth
outcome of CD40 ligation in human breast cancer cells. They
found that treatment with CD40L reduced [3H]thymidine
uptake in BT-20 and T47D cells but did not affect the growth
of CD40-negative MCF-7 or ZR-75-1 cells. These investiga-
tors observed similar results in vivo. CD40 expression has also
been shown to play a role in the activation of dendritic cells,
which are promising candidates for breast cancer immuno-
therapy [30,31]. In keeping with this finding, Pinzon-Charry
and colleagues [32] found a significantly higher proportion of
apoptotic circulating dendritic cells in patients with early-stage
breast cancer (stage I to II; n = 13) than in healthy volunteers
(n  = 15). These findings collectively show the oncogenic
potential of CD40.
Several preclinical studies from different laboratories have
suggested that the CD40 signaling pathway plays a role in the
modulation of chemosensitivity in breast cancer cells. In one
such study, Stumm and colleagues [33] reported that stimula-
tion of the CD40 receptor inhibited paclitaxel-induced apopto-
sis in breast cancer cell lines. Voorzanger-Rousselot and
colleagues [34] showed that, in breast cancer cell lines, doxo-
Figure 3
CD40 pathway gene set significantly enriched in patient's pathologic complete response and residual disease phenotypes CD40 pathway gene set significantly enriched in patient's pathologic complete response and residual disease phenotypes. (a) Plot of the running 
sum for CD40 pathway gene set in the expression data set. (b) Plot of null bimodal ES distributions (c) Heat map produced using expression data 
from CD40 pathway gene set, and sorted by pCR and RD phenotypes. ES: enrichment score; FDR: false discovery rate; FWER: family wise error 
rate; NES: normalized enrichment score; pCR: pathologic complete response; RD: residual disease.Available online http://breast-cancer-research.com/content/9/6/R87
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rubicin, cisplatin, etoposide, vinblastine, and paclitaxel
increased apoptosis in a dose-dependent manner through a
caspase-independent mechanism. Co-culture with irradiated L
cells expressing CD40L significantly reduced the percentage
of apoptotic cells in breast cancer cell lines treated with these
drugs. These experimental data are consistent with our
observation that the activation of the CD40 pathway in primary
breast tumors is associated with an improved pathologic
response to preoperative trastuzumab-plus-T/FEC
chemotherapy.
To address the potential problem of the characteristics of our
validation cohort not sufficiently matching those of the present
study cohort, we examined the predictive performance of a
previously developed 30-gene pharmacogenomic predictor of
pCR which had also been validated in patients who received
preoperative T/FAC alone, regardless of HER-2 status [17].
The genomic predictor was less accurate in the trastuzumab-
treated patients than in the patients of the validation cohort
who did not receive trastuzumab. However, the 30-gene pre-
dictor also performed well in the HER-2-positive subset of
patients included in the original validation set. This suggests
that the loss of accuracy was due to the inclusion of a new
drug, trastuzumab, rather than the application of the predictor
to a particular subset of cases. The lack of correlation between
factors known to be predictive of pCR in preoperative chemo-
therapy trials, such as ER and Ki67, can be explained by the
powerful effect of trastuzumab in patients with HER-2-overex-
pressing tumors.
Our previous work identified alterations in protein levels and
protein phosphorylation as important contributors to trastuzu-
mab resistance in vitro [35]. Potential mechanisms of trastuzu-
mab resistance include loss of PTEN (phosphatase and tensin
homolog deleted on chromosome 10) [36], cross-talk
between the HER-2 and insulin-like growth factor-I receptor
proteins [37], and downregulation of the p27kip1 protein [38].
Such protein level alterations cannot be directly measured by
transcriptional analysis; hence, it is not surprising that these
genes did not emerge as predictors from our microarray data
set. Protein level analysis of these clinical specimens has yet
to be performed. Indeed, it is possible that markers of trastu-
zumab resistance will be easier to identify at the protein level
than at the mRNA expression level.
It is important to point out that, in this study, only 36% of
patients (n = 16) had residual invasive breast cancer after 6
months of preoperative T/FEC-plus-trastuzumab therapy and
that all of these patients had some clinical response to ther-
apy. Therefore, any analysis we can perform can only compare
extreme sensitivity (that is, pCR) to lesser sensitivity (that is,
clinical response but pathologic RD). This may have limited our
ability to identify transcriptional differences between these two
response groups. Also, sample size was limited by the availa-
bility of specimens, a challenge inherent in most optional cor-
relative science studies. As similar studies are published and
more transcriptional data become publicly available, the option
to perform pooled analyses may allow investigators to study
larger data sets.
Conclusion
In summary, our findings indicate that certain clinical variables,
including grade and ER status, and a pharmacogenomic pre-
dictor of pCR which has been proven accurate in the absence
of trastuzumab are no longer accurate when trastuzumab is
included in the treatment. Our GSEA results suggest that a
CD40 gene signature may be able to identify a subset of
patients with HER-2-overexpressing breast cancer who are
more likely to achieve pCR in response to trastuzumab-plus-T/
FEC therapy.
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